PRQR
ProQR Therapeutics N.V.
There isn't enough reported data to score PRQR yet.
PRQR Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
PRQR's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
PRQR PE Valuation
PRQR has no meaningful PE right now: it lost money over the past year.
PRQR Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Decline | |
| -- | |
| Limited | |
| Low |
Analysts expect PRQR's losses to grow, with revenue declining. However, they disagree widely on these estimates.
PRQR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.41 | +$0.06 |
| Q4 2025 | -$0.44 | -$0.08 |
| Q4 2024 | -$0.36 | +$0.03 |
| Q4 2023 | -$0.39 | +$0.62 |
| Q3 2023 | -$0.49 | +$0.63 |
| Q2 2023 | -$0.79 | +$0.20 |
| Q4 2022 | -$1.01 | +$0.06 |
| Q3 2022 | -$1.12 | -$0.05 |
PRQR is still losing money, but far less than before: $0.41 per share over the past year, against $1.51 at its worst in late 2019.
PRQR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $17.7M | +453% |
| Q4 2025 | $5.2M | +8.8% |
| Q3 2025 | $3.2M | -25% |
| Q2 2025 | $4.2M | -39% |
| Q1 2025 | $5M | +1.6% |
| Q4 2024 | $4.8M | -34% |
| Q3 2024 | $4.3M | +181% |
| Q2 2024 | $7M | +423% |
PRQR's revenue is growing: $18M last quarter, up 253% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -223% | +16 points |
| Q4 2025 | -194% | +40 points |
| Q3 2025 | -392% | -165 points |
| Q2 2025 | -321% | -264 points |
| Q1 2025 | -239% | -58 points |
| Q4 2024 | -234% | +255 points |
| Q3 2024 | -227% | +313 points |
| Q2 2024 | -57% | +674 points |
PRQR's operating margin was −223% last quarter, up 16 points from the same quarter a year ago.
PRQR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$42M | -$28.2M |
| Q4 2025 | -$15.4M | -$4.9M |
| Q3 2025 | -$13.8M | -$7.2M |
| Q2 2025 | -$12.8M | -$5.5M |
| Q1 2025 | -$17.8M | -$175.5K |
| Q4 2024 | -$10.5M | -147% |
| Q3 2024 | -$6.6M | +$2.1M |
| Q2 2024 | -$7.2M | +$4.6M |
PRQR has burned cash in almost every quarter: −$84M over the past year, against −$42M the year before.
PRQR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +13% | +13.6M shares |
| 1 year | +13% | +13.7M shares |
| 3 years | +47% | +38.1M shares |
| 5 years | +137% | +68.8M shares |
| Available history | +206% | +80.1M shares |
PRQR has 119M diluted shares, up 13% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
| Q3 2019 | — |
| Q2 2019 | — |
| Q1 2019 | — |
PRQR Net Leverage
PRQR's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
PRQR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.1 | Neutral |
| Stochastic | 13.2 | Oversold |
PRQR's weekly RSI is 40 (neutral) and its Stochastic is 13 (oversold).
PRQR PE vs Healthcare Sector
PRQR has no meaningful PE right now: it lost money over the past year.
PRQR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.45 | 6.2% below |
| 20 week MA | $1.72 | 21% below |
| 50 week MA | $1.72 | 21% below |
| 100 week MA | $1.91 | 29% below |
| 200 week MA | $2.02 | 33% below |
PRQR is in a downtrend: it's below all five of its weekly moving averages, and 33% below its 200-week average.
PRQR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.41 | $4.63 | -51% |
| 2021 | $4.63 | $8.20 | +77% |
| 2022 | $8.20 | $2.71 | -67% |
| 2023 | $2.71 | $1.98 | -27% |
| 2024 | $1.98 | $2.79 | +41% |
| 2025 | $2.79 | $2.17 | -22% |
| 2026 YTD | $2.17 | $1.36 | -37% |
PRQR has finished lower in four of the last six years. It's down 37% so far in 2026.